



## **Transaction Contacts**

Coverage Team:
Mairin Rooney
Liz Meeks

ECM Team: Jack Bannister



\$300 Million
Follow-On Offering



Joint Bookrunner March 2023

## SVB Securities Serves as Joint Bookrunner for Revolution Medicines' (Nasdaq: RVMD) \$300 Million Follow-On Offering

## **Key Transaction Highlights**

- · Confidentially marketed deal that publicly launched on March 1st post-close and priced March 2nd post-close
- The offering followed Revolution Medicines' February 27th report of its Q4 and full year 2022 financial results and update on corporate progress, including early clinical data on RMC-6236 which supports validation of the Company's RAS(ON) Inhibitor platform.
- · Well oversubscribed from new and existing investors
- Transaction consisted of 13,636,364 shares of common stock at a price of \$22.00 per share, representing a 6.0% discount to last sale.
- Revolution Medicines intends to use the net proceeds from this offering, together with its existing cash, cash
  equivalents and marketable securities, to fund development of the RAS(ON) Inhibitor programs, including the
  on-going clinical development of RMC-6236 and RMC-6291 and the planned advancement of RMC-9805 into
  clinical development, the on-going clinical development of the RAS Companion Inhibitor programs, including
  RMC-4630 and RMC-5552, the advancement of preclinical programs and for other general corporate
  purposes, which may include working capital, hiring of additional personnel and capital expenditures.
- This is SVB Securities' 4th bookrun offering for Revolution Medicines and 9th bookrun equity offering in 2023.

If you would like to unsubscribe from this distribution, click here. If you would like to unsubscribe from all SVB Securities distributions, click here.

THIS EMAIL IS FOR INFORMATIONAL PURPOSES ONLY AND IS BEING FURNISHED TO INVESTMENT BANKING CLIENTS OF SVB SECURITIES LLC. THE INFORMATION INCLUDED HEREIN IS FOR YOUR INFORMATION ONLY AND MAY NOT BE REPRODUCED FOR OR REDISTRIBUTED TO ANY OTHER PURPOSES. THESE SECURITIES HAVE BEEN SOLD. THIS EMAIL IS NOT AN OFFER TO SELL, AND IS NOT SOLICITING AN OFFER TO BUY, ANY SECURITIES.

BOSTON 53 State Street 40th Floor Boston, MA 02109 CHARLOTTE 2151 Hawkins Street Suite 1025 Charlotte, NC 28203 NASHVILLE 40 Burton Hills Boulevard Suite 200 Nashville, TN 37215 NEW YORK 1301 Avenue of the Americas 12th Floor New York, NY 10019 SAN FRANCISCO 255 California Street 12th Floor San Francisco, CA 94111

An SVB Company sybsecurities.com